Researchers created their new method to analyse chromosomes in 3D, revealing how misconfigurations play a role in cancer.
List view / Grid view
A spatial atlas of early-stage lung cancer has been compiled at single-cell resolution, revealing new therapeutic targets.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
New research shows tissue damage to cells carrying KRAS mutations induces epigenetic changes that promote pancreatic cancer.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
When it comes to developing antibody drugs, Dr Jerome Boyd-Kirkup and his team are not sticking to the classical playbook. Here, he explains how they use systems biology and immuno-engineering to remove the element of luck from biologic drug discovery and development.
A new cancer-killing virus called CF33 has shown success in pre-clinical trials, helping the immune system to eradicate tumours.
Researchers demonstrate that inhibiting the LMTK3 kinase is an effective anticancer strategy in murine models of breast cancer.
By targeting the mutated KRAS gene, researchers have developed an experimental vaccine that protected mice against a range of cancers.
Researchers have implicated long non-coding RNAs in tumour progression and suggest they may be potential drug targets for cancers with p53 mutations.
Using CRISPR to cut out fusion genes, scientists were able to specifically induce cancer cell death in murine models of sarcoma and leukaemia.
After finding that the circular RNA called CDR1as plays a role in driving metastasis, researchers have identified it as a potential target for lung squamous cancer.
A study has shown that inhibiting sortilin, a neuroprotein known to have increased expression in cancers, reduces pancreatic cancer invasiveness in vitro.
The proteomic map based on data from 103 patients reveals novel prognostic biomarkers and potential drug targets for lung adenocarcinoma.